Pulmonary (Arterial) Hypertension Study



Trial Objective

The study looks to identify the minimal and maximum effective dose of inhaled nitric oxide using an investigational drug/device combination product, the GeNO NITROsyl™ System, when compared to placebo (air).
 
Pulmonary hypertension (PH) refers to a condition in which high blood pressure exists within the vessels of the lungs. Pulmonary arterial hypertension (PAH) is one of five types of PH in which the pressure in the arteries of the lungs becomes extremely high; this high blood pressure then puts a strain on the heart.

This study is 60 days in duration (1 day for right heart catheterization and a follow up phone call 30 days later) and includes diagnostic cardiac testing, electrocardiogram and echocardiogram procedures.
 

Pulmonary (Arterial) Hypertension Study

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Valerie Snyder at 303.270.2591 or complete the form below.

Who Can Participate

  • At least 18 years of age
  • Diagnosed with pulmonary hypertension (PH) OR
  • Diagnosed with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF)
  • Your doctor is planning to schedule you for a right heart catheterization

Trial Location

Main Campus

Compensation

Yes

Principal Investigators

  • image description
    Brett Fenster, MD, FACC, FASE

Request More Information

*
*
*
*